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OBJECTIVE—To evaluate vitamin D as a predictor of all-cause mortality, progression from
normoalbuminuria to micro- or macroalbuminuria, and the development of background or
proliferative retinopathy in patients with type 1 diabetes.
RESEARCHDESIGNANDMETHODS—Aprospectiveobservationalfollow-upstudyin
which an inception cohort of type 1 diabetic patients was followed from onset of diabetes di-
agnosedbetween1979and1984.PlasmavitaminD[25(OH)D3]levelsweredeterminedbyhigh
performance liquid chromatography/tandem mass spectrometry in 227 patients before the
patients developed microalbuminuria. Values equal to or below the 10% percentile (15.5
nmol/L) were considered severe vitamin D deﬁciency.
RESULTS—Median(range)vitaminDwas44.6(1.7–161.7)nmol/L.VitaminDlevelwasnot
associated with age, sex, urinary albumin excretion rate (UAER), or blood pressure. During
follow-up, 44 (18%) patients died. In a Cox proportional hazards model, the hazard ratio
for mortality in subjects with severe vitamin D deﬁciency was 2.7 (1.1–6.7), P =0 . 0 3 ,a f t e r
adjustment for UAER, HbA1c, and conventional cardiovascular risk factors (age, sex, blood
pressure, cholesterol, smoking). Of the 220 patients, 81 (37%) developed microalbuminuria
and 27 (12%) of these progressed to macroalbuminuria. Furthermore, 192 (87%) patients
developedbackgroundretinopathy,whereas34(15%)progressedtoproliferativeretinopathy.
SeverevitaminDdeﬁciencyatbaselinedidnotpredictthedevelopmentofthesemicrovascular
complications.
CONCLUSIONS—In patients with type 1 diabetes, severe vitamin D deﬁciency indepen-
dently predicts all-cause mortality but not development of microvascular complications in the
eye and kidney. Whether vitamin D substitution in type 1 diabetic patients can improve the
prognosis remains to be investigated.
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H
ypovitaminosis D is found to be
highlyprevalentworldwide(1).Re-
cently, low levels of vitamin D have
been associated with an increased risk of
excess all-cause and cardiovascular mor-
tality in the general population (2) as well
asintype2diabeticpatients(3).However,
toourknowledgetheassociationhasnever
been investigated in type 1 diabetic sub-
jects. The levels of plasma vitamin D (25-
hydroxyvitamin D3 [25(OH)D3]) varies
considerably among individuals mainly
because of differences in sun exposure,
skin color, and the presence of risk factors
such as diabetes or other comorbidities.
In patients with diabetes, an excess
mortality in patients with diabetes com-
plicationshasbeenestablished(4).Devel-
opment and progression of diabetic
microangiopathy in terms of retinopathy
and nephropathy is known to be closely
related to poor metabolic control, elevated
arterial blood pressure, and other risk fac-
tors(5,6).Datafromstudiesinexperimen-
tal diabetic nephropathy indicate that
vitamin D insufﬁciency may also be in-
volvedinthepathogenesisofalbuminuria.
Inthegeneralpopulation, aninverse asso-
ciation is found between the level of vita-
min D and the prevalence of albuminuria
(7), and limited data from clinical trials
in nondiabetic chronic kidney disease
(CKD) patients suggest that treatment
withparicalcitol(vitaminDreceptoranalog
[VDRA]) may reduce proteinuria (8–10).
Furthermore,recentlypublisheddatasug-
gest that administration of a VDRA on top
of blockade of the rennin angiotensin al-
dosterone system (RAAS) in patients with
type 2 diabetes and diabetic nephropathy
lowers albuminuria (11). Diabetes is the
leading cause of CKD and kidney failure
in the Western world, but it is unclear if
vitamin D insufﬁciency contributes to the
risk of developing diabetic nephropathy or
other microvascular complications. With
this study we aimed to investigate whether
very low levels of plasma 25(OH)D3 could
predict increased risk of excess mortality
as well as development of microvascular
complications in type 1 diabetic patients.
RESEARCH DESIGN AND
METHODS—Our study sample com-
prised all patients newly diagnosed with
type 1 diabetes consecutively admitted
to the Steno Diabetes Center between 1
September 1979 and 31 August 1984.
The inception cohort included 286 pa-
tients.Ninepatientswereexcluded;seven
because of serious mental illness and two
because of microalbuminuria at the onset
of diabetes. Plasma 25(OH)D3 was ana-
lyzed in samples from approximately 3
years after diagnosis or the subsequently
closest available sample (median [range]
years after diagnose = 3.0 [2.3–9.1]) and
before any of the patients developed mi-
croalbuminuria. Samples were available
in 220 patients.
The patients attended the outpatient
clinic every 3 or 4 months as part of
routine follow-up. They were treated by
diabetologists and nurses according to
previously described guidelines (12).
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ORIGINAL ARTICLEThey received no speciﬁc intervention.
Twenty-four hoururinary albumin excre-
tion rate (UAER) was measured in each
patient at least once a year (12). Develop-
ment of persistent microalbuminuria and
persistent macroalbuminuria were de-
ﬁned as UAER between 30 and 300 mg/
24 h and .300 mg/24 h, respectively, in
at least two of three consecutive samples,
with an increase of at least 30% above the
baseline level (13,14).
Plasma 25(OH)D3 was measured
from samples stored at 220°C until anal-
ysis. All samples were treated and stored
under the same conditions. Plasma 25
(OH)D3 is found to be stable when tested
after more than 10 years of storage (15),
making long-term epidemiologic studies
ofcirculatingplasma25(OH)D3possible.
Before initiation of the current study, we
tested the stability of plasma 25(OH)D3
in samples taken from this exact cohort.
We analyzed plasma 25(OH)D3 in sam-
ples taken from the same subjects at the
sametime ofyearand storedfor5,10,15,
20, and 25 years. No statistical signiﬁcant
difference between mean levels of plasma
25(OH)D3 was shown (data not shown).
Plasma levels of 25(OH)D3 were de-
termined by high performance liquid
chromatography/tandem mass spectrom-
etry (Department of Clinical Biochemis-
try, Lillebælt Hospital, Vejle, Denmark).
A plasma 25(OH)D3 value equal to or be-
lowthe10%percentile(15.5nmol/L)was
considered severe vitamin D deﬁciency
in accordance with our previous study
on vitamin D and mortality in type 2 di-
abetes (3).
Patients were classiﬁed as smokers
if they smoked more than one cigarette
a day; smoking history was elicited by
questionnaire.Retinopathywasassessed
through dilated pupils and graded as
absent, background, or proliferative
(12).
Statistical analysis
Baseline data are from ﬁrst assessment 6
months after the onset of type 1 diabetes,
after initial glycemic stabilization. Vari-
ables with skewed distribution are ex-
pressed as medians (interquartile range);
values for all other variables are means
(SD).
For nonnormally distributed vari-
ables, comparisons between groups were
performed using the Mann-Whitney U
test, and unpaired Student t tests were
used for normally distributed variables.
A x
2 test was used for comparison of cat-
egorical variables between groups.
To evaluate whether low vitamin D
levels predicted all-cause mortality in an
explanatory model, a Cox proportional
hazardsregressionanalysiswasperformed.
Initially, a univariate analysis was per-
formed using baseline variables (sex, age,
plasma total cholesterol, systolic blood
pressure, UAER, smoking), all which have
previously been shown to be associated
with increased all-cause mortality. Results
are described as hazard ratios (HRs) with
95% CIs.
All time-to-event variables were ana-
lyzedwithalog-ranktestanddisplayedas
Kaplan-Meier plots according to levels of
vitaminDeitheraboveorbelowthelower
10% percentile. Two-tailed P values
#0.05 were considered statistically sig-
niﬁcant. All statistical calculations were
performed using SPSS for Windows, ver-
sion 14.0 (SPSS, Chicago, IL)
RESULTS—We followed 220 patients
newly diagnosed with type 1 diabetes
for a median (range) of 26.0 (1.0–29.0)
years. The main baseline patient charac-
teristicsareshowninTable1.Themedian
(range) vitamin D concentration was 44.6
(1.7–161.7) nmol/L.
The patients were divided into two
subgroups based on their vitamin D level
being either equal to and below or above
thevalueofthelower10%percentile.The
cut off value for the lower 10% percentile
wasvitaminD#15.5nmol/Linbothmen
and women, and 22 (10%) of the 220 in-
cluded patients with a vitamin D value
below this level. Vitamin D level was not
associated with age, sex, UAER, and
blood pressure, but a weak negative
association was found with HbA1c. (R =
0.14, P = 0.04).
During follow-up, 44 (20%) of the
220 patients died. Seven of the 22 (32%)
patients with vitamin D levels #15.5
nmol/L died compared with 37 (19%) of
the patients with vitamin D levels .15.5
nmol/L (P = 0.06). Figure 1 shows a
Kaplan-Meier curve for mortality accord-
ingtoavitaminDlevelequaltoandbelow
or above the lower 10% percentile. In a
Cox proportional hazards model, the un-
adjusted HR (95% CI) for mortality in
subjects with vitamin D levels equal to
or below the lower 10% percentile was
2.0 (0.9–4.4), P = 0.1. The association
persisted and became statistically signiﬁ-
cant after adjustment for UAER, HbA1c,
and conventional cardiovascular risk fac-
tors(age,sex,bloodpressure,cholesterol,
smoking) (covariate adjusted HR 2.7
[1.1–6.7], P = 0.03). An analysis of vita-
min D as a continuous variable in the Cox
model could not demonstrate a signiﬁ-
cant relation to all-cause mortality, sug-
gesting the relationship is not linear over
the range of vitamin D values.
Microvascular complications
During follow-up, 81 (34%) patients de-
veloped persistent microalbuminuria. Of
these patients, 6 (27%) had a vitamin D
level equal to or below the lower 10%
percentile. Of the 81 patients who de-
veloped microalbuminuria, 27 (12%)
progressed to persistent macroalbumin-
uria,butonly2ofthepatientswithvitamin
D levels equal to or below the lower 10%
percentile progressed, corresponding to
9%.
Table 1—Baseline clinical and laboratory characteristics of 220 type 1 diabetic patients
in accordance with levels of 25(OH)D3
25(OH)D3
.15.5 nmol/L
25(OH)D3
#15.5 nmol/L P
n 198 22
Sex (male/female) 117/81 14/8 1.0
Age (years) 29 (14) 31 (16) 0.5
BMI (kg/m
2) 20.6 (2.6) 20.2 (2.9) 0.5
HbA1c (%) 9.8 (2.1) 10.6 (2.5) 0.1
Urinary albumin excretion (mg/24 h) 9 (6–14) 9 (5–11) 0.3
Serum creatinine (mmol/L) 80 (14) 77 (16) 0.3
Systolic blood pressure (mmHg) 125 (17) 129 (16) 0.3
Diastolic blood pressure (mmHg) 78 (11) 79 (10) 0.6
Serum cholesterol (mmol/L) 5.5 (1.5) 5.6 (1.4) 0.7
Smokers/nonsmoker/former smoker 85/63/50 11/7/4 0.7
Vitamin D, 25(OH)D3 (nmol/L) 46.6 (30.9–62.7) 11.4 (8.9–11.4) —
Data are n, means (SD), or medians (interquartile range).
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showed that low vitamin D levels at
baseline did not predict the development
of micro- or macroalbuminuria (unad-
justed HR 1.1 [0.5–2.4], P = 0.8 and HR
1.3 [0.3–5.4], P = 0.7, respectively).
A total of 192 (80%) patients devel-
oped background retinopathy, and 18
(82%) ofthepatientshad vitaminDlevels
equaltoorbelowthelower10%percentile.
Of the 192 patients, 34 (15%) patients
progressedtoproliferativeretinopathy,and
one of these patients had low vitamin D
level at baseline, corresponding to 5%.
Vitamin D levels equal to or below the
lower 10% percentile at baseline did not
predict development of background reti-
nopathy or proliferative retinopathy (HR
1.1 [0.7–1.7], P = 0.8 and HR 3.1 [0.4–
22.9], P = 0.3, respectively).
After adjusting for progression pro-
moters, the associations between severe
vitamin D deﬁciency at baseline and de-
velopment or progression of microvascu-
lar complications weakened further.
CONCLUSIONS—In this 26-year
prospective observational follow-up
study, we found very low levels of plasma
25(OH)D3 (equal to or below the 10%
percentile) after onset of diabetes to be a
strong and independent predictor of all-
causemortalityintype1diabeticpatients.
This association was not only indepen-
dent of glycemic control and conven-
tional cardiovascular risk factors, but
also independent of UAER. Severe vita-
min D deﬁciency at baseline did not
predict development or progression of
microvascular complications in the eye
and kidney.
Ourﬁndingofanassociationbetween
severe vitaminDdeﬁciency and increased
risk of mortality complement recent data
from epidemiological studies suggesting
similar associations in other popula-
tions. For the general population, a cross-
sectional study of 13,331 participants
from the National Health and Nutrition
Examination Survey (NHANES) III (2)
showed low vitamin D levels to be associ-
ated with all-cause mortality. A study of
mainly nondiabetic CKD patients (16)
found vitamin D to independently predict
all-cause mortality and increased risk of
progression to dialysis. Also among pa-
tients with nondiabetic end-stage renal
disease, low levels of vitamin D have
been associated with all-cause mortality
(17).
In healthy subjects, vitamin D de-
ﬁciency mainly results from inadequate
sunlight exposure, skin color, and inad-
equate nutritional supply of vitamin D–
containing foods. Seasonal variations in
vitamin D levels occur depending on geo-
graphic latitude and sun exposure in par-
ticularly. A study (18) done in the general
populationinaNorthernEuropeancoun-
tryshowedaseasonal variationofvitamin
Di n s u f ﬁciency of 73% and 29% for win-
ter and summer, respectively. The differ-
ence for vitamin D deﬁciency was
similarly found to be 8% and 1%. Fur-
thermore, several conditions such as obe-
sity and absorption, liver, or kidney
disorders pose an increased risk of devel-
oping vitamin D deﬁciency.
The mechanisms of action behind the
increased mortality risk seen among pa-
tientswiththe lower levelsofvitaminDat
baseline are unclear. A growing amount
of evidence indicates that vitamin D,
through activation of the vitamin D re-
ceptor, has clinically important noncal-
cemicpleiotropiceffects.Activationofthe
vitamin D receptor is associated with
suppression of the RAAS (19), cardiac
myocyte hypertrophy (20), vascular cal-
ciﬁcation, and atherosclerosis lowering,
anti-inﬂammatory (21), and immuno-
modulatory actions. Also, an inverse re-
lationship is found between vitamin D
and increased incidentrisk of certain can-
cers as well as a higher mortality from
these cancers (1).
Diabetic patients have a higher rate of
cardiovascular morbidity and mortality
compared with the general population.
In a 10 year follow-up study of a cohort
of 593 normoalbuminuric patients
with type 1 diabetes, we have previously
shown that more than one-third died of
known cardiovascular causes and 25%
died of unknown, potentially cardiovas-
cular causes (4), hence a large number of
the observed deaths in the cohort of the
current study are likely to be from cardio-
vascular causes.
In a cross-sectional study of type 2
diabetic patients with mild kidney im-
pairment, vitamin D deﬁciency was
shown to be strongly associated with a
higher prevalence of manifest cardiovas-
cular disease when compared with nor-
mal vitamin D status (22).
Several of the above mentioned path-
ways may be important mechanisms in
cardiovascular health. In a recent study of
type2diabeticpatients(23),whichinves-
tigated the mechanism by which vitamin
Dd e ﬁciency mediates increased risk of
Figure 1—Kaplan-Meier curves of all-cause mortality in 220 type 1 diabetic patients in accor-
dancewithavitaminDlevelequaltoandbeloworabovethelower10%percentile,25(OH)D3=15.5
nmol/L. Full black line, 25(OH)D3 .15.5 nmol/L; dashed black line, 25(OH)D3 #15.5 nmol/L.
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f o u n dar e d u c e dv i t a m i nDr e c e p t o r
signaling to be a potential mechanism
underlying increased foam cell (macro-
phages that ingested oxidized LDL) for-
mation and accelerated cardiovascular
d i s e a s ei nd i a b e t i cc o m p a r e dw i t hn o n -
diabetic patients.
Given the observational design, the
current study does not elaborate further
on underlying mechanisms but indirectly
adds to the increasing amount of data
suggesting that vitamin D substitution
might be a potential therapeutic target to
prevent vascular disease progression.
However, it is not possible to rule out
that low levels of vitamin D may result
fromasingleyetunidentiﬁedfactorthatis
at the same time responsible for the in-
creased risk seen in this study.
The pathogenesis behind microvas-
cular complications in diabetes is com-
plex and thought to involve multiple
pathways. Development of microalbumin-
uria in diabetic patients is closely associ-
ated with an increased risk of both renal
and cardiovascular disease. It has been
suggested that microalbuminuria often
regresses to normoalbuminuria, but in
this cohort, spontaneous and permanent
regressionto normoalbuminuria occurred
in only 16% of the patients progressing to
microalbuminuria, whereas 34% pro-
gressed to persistent macroalbuminuria
during follow-up (24). Of particular im-
portance to diabetic nephropathy is an ac-
tivation of the intrarenal RAAS and the
proinﬂammatory nuclear factor-kB path-
way, both promoting progressive renal
damage. In a post hoc analysis, Agarwal
et al. (10) found that administration of a
VDRA compared with placebo caused
reduction in albuminuria in nondiabetic
CKD as measured by a dipstick method
(P = 0.004). Importantly, the effects ap-
peared to be independent of concomitant
therapiestoinhibittheRAAS.Recentlythe
VITAL study, a randomized controlled
clinical trial with 281 type 2 diabetic pa-
tients with diabetic nephropathy, has
shown that administration of a VDRA
(paricalcitol) in addition to blockade of
the RAAS causes sustained reduction in
albuminuria and thereby potentially has
clinically relevant renoprotective effects
in patients with diabetic nephropathy
(11).
A cross-sectional study of 581 type 2
diabetic patients shows signiﬁcant as-
sociation between the existence of pro-
liferative retinopathy and a decrease in
25(OH)D3. Also, investigators found a
decrease in 25(OH)D3 according to the
number of microvascular complications
present (25). A cross-sectional design
does not contribute to clariﬁcation on
causality and effect, but fuels speculation
thatlowlevelsofvitaminDmightbearisk
marker of development or progression of
both diabetic nephropathy and/or reti-
nopathy. In this study, however, we did
not ﬁnd low 25(OH)D3 levels to signiﬁ-
cantly predict development or progres-
sion of microvascular complications.
Thiscouldbebecauseofthelackofpower
b a s e do nal o wn u m b e ro fe v e n t sa st h e
HR for both retinopathy and albuminuria
was above 1 in patients with severe vita-
min D deﬁciency. It is also possible that
a potentially damaging effect of low
vitamin D is offset by optimized patient
treatment aiming at improving blood
glucose and lowering blood pressure in-
clusive of RAAS blockade.
In our study, severe vitamin D de-
ﬁciency was deﬁned as the lower 10%
percentile [plasma 25(OH)D3 #15.5
nmol/L] in both men and women. Inter-
national consensus is lacking in regard to
deﬁnitions of what vitamin D levels are
to be regarded as normal, insufﬁciency,
anddeﬁciency.Thelimitsforaphysiolog-
icaloptimalvitaminDlevelarestillamat-
ter of debate in the literature. Although
25(OH)D3 is shown to be stable in stored
samples (15), storing could affect abso-
lute concentrations because of evapora-
tion, thus we arbitrarily chose the lower
10% percentile rather than an absolute
value. We have previously used the same
method to deﬁne the cutoff in a follow-up
study in type 2 diabetic patients (3). Fur-
thermore, we have recently analyzed
plasma 25(OH)D3 in fresh samples from
200 type 2 diabetic patients and we found
the lower 10% percentile in these patients
to deviate only 0.1 nmol/L from the Dan-
ish national deﬁnition of severe vitamin D
deﬁciency existing at the time.
The stability of plasma 25(OH)D3
levels in our samples was tested before
analysis as previously described. No sta-
tistically signiﬁcant difference in levels
was found when compared according to
years of storage.
Our study has some strengths and
limitations. One element of methodolog-
ical strength is the prospective design and
long follow-up period as well as com-
pleteness of follow-up. Given the obser-
vational design, it is not possible to infer
causality from the associations described.
Further limitations of our study are
related to possible changes in the level of
vitamin D throughout the year. We did
not adjust for seasonal change. Nor did
wehavebaselinedataonphysicalactivity,
which could be related to outdoor activ-
ity, sun exposure and thereby levels of
vitamin D. Vitamin D levels are also
inﬂuenced by nutritional status. Unfortu-
nately no nutritional parameters were
available except BMI, which was not re-
latedtovitaminDlevels(datanotshown).
We were therefore not able to adjust for
any of these possible cofounders, but in
general, the patients were young and
healthy apart from newly diagnosed type
1d i a b e t e s .
More observational studies are
needed to conﬁrm this ﬁnding, but as
mentioned, we have performed the same
analysis in a cohort consisting of type 2
diabeticpatientsandfoundsimilarresults
in regards to all-cause mortality and
development/progression of diabetic ne-
phropathy. Furthermore, in the study
comprising type 2 diabetic patients, very
low levels of 25(OH)D3 were also able to
predict an increased risk of cardiovascular
disease. Another limitation to the current
study is that we do not have access to data
on the cause of death.
In conclusion, with the present pro-
spective follow-up study we are now able
to show that baseline levels of 25(OH)D3
equal to or below the 10% percentile
predict increased risk of all-cause mortal-
ity in type 1 diabetic patients, as already
shown for the general population, in
patients with nondiabetic CKD and for
patientswithtype2diabetes(3).Wewere
notabletodemonstrateanassociationbe-
tween baseline levels of 25(OH)D3 equal
to or below the 10% percentile and devel-
opment of microvascular complications in
type 1 diabetic patients. Randomized
controlled clinical trials administrat-
ing VDRA are necessary in order to
prove causality between vitamin D status
and survival prognosis in diabetic
patients.
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